secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001104659-24-078464
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco completes sale of aqua business to Merck for ~$1.3B; debt reduction plan outlined
--------------------------------------------------------------------------------

- Sale to Merck closed July 9 for ~$1.3B cash; net proceeds ~$1.05-1.1B for Q3 debt paydown.
- Expected total debt paydown of ~$1.3-1.4B in 2024 from sale proceeds and base business cash flow.
- Net debt to adjusted EBITDA target: mid-4x at 2024 year-end; improving to high-3x to low-4x in 2025.
- Divestiture focuses Elanco on pet health and livestock; CFO cites three quarters of underlying revenue growth.
- Additional financial outlook impact to be provided on Q2 2024 earnings call in August.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465924078464/0001104659-24-078464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465924078464/tm2419092d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-078464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer